LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

Home・Listă Acțiuni・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Deschisă

3.84 -0.26

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.76

Maxim

3.91

Indicatori cheie
By Trading Economics
Venit	-511K -28M
Vânzări	-13M 2.6M
EPS	-0.47
Marjă de profit	-1,077.401
Angajați	141
EBITDA	-455K -29M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+285.24% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-7.5M 227M
Deschiderea anterioară	4.1
Închiderea anterioară	3.84

Voyager Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 mai 2026, 22:47 UTC

Câștiguri

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mai 2026, 20:45 UTC

Câștiguri

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mai 2026, 22:37 UTC

Market Talk

Achiziții, Fuziuni, Preluări

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mai 2026, 22:04 UTC

Achiziții, Fuziuni, Preluări

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mai 2026, 22:04 UTC

Achiziții, Fuziuni, Preluări

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mai 2026, 21:12 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mai 2026, 21:00 UTC

Câștiguri

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mai 2026, 20:57 UTC

Câștiguri

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:55 UTC

Câștiguri

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 mai 2026, 20:48 UTC

Acțiuni populare

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mai 2026, 20:34 UTC

Câștiguri

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mai 2026, 20:31 UTC

Câștiguri

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mai 2026, 20:28 UTC

Câștiguri

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mai 2026, 20:26 UTC

Câștiguri

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:20 UTC

Câștiguri

Costco 3Q Membership Fees $1.37B

28 mai 2026, 20:20 UTC

Câștiguri

Costco 3Q Net Sales $69.15B

28 mai 2026, 20:19 UTC

Câștiguri

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mai 2026, 20:19 UTC

Câștiguri

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mai 2026, 20:17 UTC

Câștiguri

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mai 2026, 20:17 UTC

Câștiguri

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparație

Modificare preț

Voyager Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

285.24% sus

Prognoză pe 12 luni

Medie 15.14 USD 285.24%

Maxim 25 USD

Minim 8 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVoyager Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Voyager Therapeutics Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.